dc.contributor.author | Bliss, JM | |
dc.contributor.author | Tovey, H | |
dc.contributor.author | Evans, A | |
dc.contributor.author | Holcombe, C | |
dc.contributor.author | Horgan, K | |
dc.contributor.author | Mallon, E | |
dc.contributor.author | Vidya, R | |
dc.contributor.author | Skene, A | |
dc.contributor.author | Dodson, A | |
dc.contributor.author | Hills, M | |
dc.contributor.author | Detre, S | |
dc.contributor.author | Zabaglo, L | |
dc.contributor.author | Banerji, J | |
dc.contributor.author | Kilburn, L | |
dc.contributor.author | Morden, JP | |
dc.contributor.author | Robertson, JFR | |
dc.contributor.author | Smith, I | |
dc.contributor.author | Dowsett, M | |
dc.contributor.author | POETIC Trialists, | |
dc.date.accessioned | 2023-04-03T10:33:12Z | |
dc.date.available | 2023-04-03T10:33:12Z | |
dc.date.issued | 2023-04-12 | |
dc.identifier.citation | Breast Cancer Research, | |
dc.identifier.issn | 1465-542X | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/5728 | |
dc.description.abstract | PURPOSE: Ki67 assessed at diagnosis (Ki67baseline) is an important prognostic factor in primary oestrogen receptor-positive (ER +) breast cancer. Proportional change in Ki67 after 2 weeks (∆Ki672week) is associated with clinical benefit from endocrine therapies and residual Ki67 (Ki672week) with recurrence-free survival. The aim was to define the association between Ki67baseline and after aromatase inhibitor (AI) exposure ∆Ki672week and Ki672week with key prognostic and biologic factors utilising data from the POETIC study. PATIENTS AND METHODS: In POETIC 4480 postmenopausal patients with primary ER and/or PgR + breast cancer were randomised 2:1 to 2 weeks' presurgical AI (anastrozole or letrozole) or no presurgical treatment (control). Ki67 was measured centrally in core-cut biopsies taken prior to AI and in core-cuts or the excision biopsy at surgery. Relationships between the Ki67 and biologic factors were explored using linear regression. RESULTS: Established associations of Ki67baseline with biologic factors including PgR status, tumour grade, tumour size, histological subtype, nodal status, and vascular invasion were confirmed in the HER2- subpopulation. In the HER2 + subpopulation only grade and tumour size were significantly associated with Ki67baseline. In control group Ki672week was 18% lower than Ki67baseline (p < 0.001) when Ki672week was measured in excision biopsies but not when measured in core-cuts. Median suppression by AIs (∆Ki672week) was 79.3% (IQR: -89.9 to -54.6) and 53.7% (IQR: -78.9 to -21.1) for HER2-negative and HER2-positive cases, respectively. Significantly less suppression occurred in PgR- vs PgR + and HER2 + vs HER2- tumours which remained apparent after adjustment for 2-week sample type. CONCLUSIONS: The magnitude of this study allowed characterisation of relationships between Ki67baseline, ∆Ki672week and Ki672week with high degrees of confidence providing a reference source for other studies. Lower values of Ki67 occur when measured on excision biopsies and could lead to apparent but artefactual decreases in Ki67: this should be considered when either ∆Ki672week or Ki672week is used in routine clinical practice to aid treatment decisions or in clinical trials assessing new drug therapies. | |
dc.language.iso | eng | |
dc.publisher | BMC | |
dc.relation.ispartof | Breast Cancer Research | |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | |
dc.title | Clinico-pathologic relationships with Ki67 and its change with short-term aromatase inhibitor treatment in primary ER + breast cancer: further results from the POETIC trial (CRUK/07/015). | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2023-02-27 | |
dc.date.updated | 2023-03-20T14:47:08Z | |
rioxxterms.version | AM | |
rioxxterms.type | Journal Article/Review | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Clinical Trials & Statistics Unit | |
pubs.publication-status | Accepted | |
icr.researchteam | Clin Trials & Stats Unit | |
dc.contributor.icrauthor | Bliss, Judith | |
dc.contributor.icrauthor | Tovey, Holly | |
dc.contributor.icrauthor | Kilburn, Lucy | |
icr.provenance | Deposited by Mrs Jessica Perry (impersonating Prof Judith Bliss) on 2023-03-20. Deposit type is initial. No. of files: 1. Files: POETIC_Ki67_manuscript_v6.2_CLEAN.pdf | |